Background: Currently, there is a lack of systematic research
on the prognostic variables of metastatic cervical cancer (mCEC) among
young and middle-aged females. Therefore, this research is purposed to
identify the independent prognostic markers in mCEC patients
(< 50 years of age) and to develop the nomograms applicable to
predict their prognosis. Materials and Methods: The data on
patients pathologically proven to have cervical cancer between 2004 and
2015 were collected from the American detection, epidemiology, and
results (SEER) database. Then, univariate and multivariate cox analyses
were conducted to determine independent prognostic variables. On this
basis, nomograms were constructed to predict the 12-, 24-, and 36-month
overall survival (OS) of mCEC patients aged under 50. The model was
evaluated for predictive accuracy, discriminant ability, and clinical
value through the receiver operating characteristic curve, the
calibration curve and the decision-making curve analysis. Additionally,
a survival calculator based on nomogram and network was developed.
Results: A total of 616 mCEC patients aged under 50 were
involved in the research. They were divided into a training set (419)
and a validation set (176), at a ratio of 7:3. The independent
predictive markers include race, tumour size, T stage, chemotherapy,
radiotherapy, and surgery. According ot the analysis of the calibration
curve, receiver operating characteristic curve, and decision curve
plotted for both the training and validation cohorts, the NOMOGRAMS was
highly discriminative and applicable clinically. The AUC value at 12,
24, and 36 months was 0.741, 0.739, and 0.731 in the training set, and
0.760, 0.695, and 0.696 in the validation set, respectively. The
nomograms proposed in this paper can be accessed via the link:
[https://shubei11.shinyapps.io/Youngcervicalnomogram/.](https://shubei11.shinyapps.io/Youngcervicalnomogram/.)
In addition, a method novel risk categorization was developed to
categorise all patients into three groups depending on their prognosis.
Conclusions: In this study, a unique web-based nomogram is
developed to estimate the risk of OS among the young and middle-aged
mCEC patients (< 50), which would be beneficial for clinicians
to personalise both survival evaluation and therapeutic treatment for
patients.